Tel Aviv University in Pact for Alzheimer's Research

Tel Aviv University has signed a multi-year research, license and development agreement with drug companies Elan Corporation and American Home Products Corporation to collaborate on the research and development of immunological approaches for the treatment and prevention of Alzheimer's disease.

Elan and AHP have acquired co-exclusive worldwide rights to a group of technologies development by researchers at Tel Aviv University, which make up novel immunological approaches for the treatment and prevention of Alzheimer's.

The agreement with Tel Aviv University builds upon an existing collaboration between Elan and AHP for research, development and commercialization of an experimental therapy called AN-1792, an immunotherapeutic approach for Alzheimer's that is currently in clinical trials.

"We are very excited," said Professor Itamar Rabinovich, President of the university and a former Israeli Ambassador to the United States. "We expect that through this collaboration Tel Aviv University will make a major contribution to the development of new treatments for one of the most devastating diseases affecting the aging population around the world.

Other sources: Tel Aviv University